1 July 2019 - The Korean branch of Eli Lilly said that it had gained additional reimbursement for its psoriasis treatment Taltz (ixekizumab) for treating active and progressive psoriatic arthritis from the Ministry of Health and Welfare.

The decision comes after the company received insurance benefits for treating patients with chronic severe plaque psoriasis in August last year.

The latest move covers patients with active and progressive psoriatic arthritis, who had an insufficient response to one or more TNF-α inhibitors or have discontinued treatment due to side effects or contraindications and has seen more than 30 percent reduction in the number of active joints after using Taltz for three months.

Read Korea Biomedical Review article